Philadelphia Business Journal -- GlaxoSmithKline has settled 5,500 cases related to its diabetes drug Avandia for $250 million, or an average of $46,000 each, the Philadelphia Inquirer reports in a Bloomberg story.
Philadelphia Business Journal -- GlaxoSmithKline has settled 5,500 cases related to its diabetes drug Avandia for $250 million, or an average of $46,000 each, the Philadelphia Inquirer reports in a Bloomberg story.
